David G Huntsman - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

David G Huntsman

Showing results (141-150 of 320) with videos related to

Pageof 32

Sort By:

Cancer Cell International|January 15, 2019

Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic targetMarta Llaurado Fernandez, Amy Dawson, Joshua Hoenisch, et al.

The Journal of Molecular Diagnostics : JMD|November 5, 2016

FOXL2 402C>G Mutation Can Be Identified in the Circulating Tumor DNA of Patients with Adult-Type Granulosa Cell TumorAnniina Färkkilä, Melissa K McConechy, Winnie Yang, et al.

Cancer|January 7, 2017

Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancerAline Talhouk, Melissa K McConechy, Samuel Leung, et al.

International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 5, 2025

Co-existent endometrial and ovarian carcinoma: molecular and pathological features define low risk entityAmy Jamieson, Jutta Huvila, Samuel Leung, et al.

Human Pathology|April 29, 2014

ARID1A/BAF250a as a prognostic marker for gastric carcinoma: a study of 2 cohortsKimberly C Wiegand, Keiyan Sy, Steve E Kalloger, et al.

Cancer Research|July 24, 2021

Modeling High-Grade Serous Ovarian Carcinoma Using a Combination of <i>In Vivo</i> Fallopian Tube Electroporation and CRISPR-Cas9-Mediated Genome EditingKatie Teng, Matthew J Ford, Keerthana Harwalkar, et al.

International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|July 31, 2018

Tubo-Ovarian Transitional Cell Carcinoma and High-grade Serous Carcinoma Show Subtly Different Immunohistochemistry ProfilesJamie Magrill, Anthony N Karnezis, Basile Tessier-Cloutier, et al.

NPJ Precision Oncology|July 19, 2024

Learning generalizable AI models for multi-center histopathology image classificationMaryam Asadi-Aghbolaghi, Amirali Darbandsari, Allen Zhang, et al.

The Journal of Pathology|August 29, 2012

The autophagy protein LC3A correlates with hypoxia and is a prognostic marker of patient survival in clear cell ovarian cancerJaeline E Spowart, Katelin N Townsend, Hassan Huwait, et al.

Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 27, 2016

Concurrent ARID1A and ARID1B inactivation in endometrial and ovarian dedifferentiated carcinomasMackenzie Coatham, Xiaodong Li, Anthony N Karnezis, et al.

Pageof 32

Search research articles

Showing results (141-150 of 320) with videos related to

Sort By:

Pageof 32

Cancer Cell International|January 15, 2019

Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic targetMarta Llaurado Fernandez, Amy Dawson, Joshua Hoenisch, et al.

The Journal of Molecular Diagnostics : JMD|November 5, 2016

FOXL2 402C>G Mutation Can Be Identified in the Circulating Tumor DNA of Patients with Adult-Type Granulosa Cell TumorAnniina Färkkilä, Melissa K McConechy, Winnie Yang, et al.

Cancer|January 7, 2017

Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancerAline Talhouk, Melissa K McConechy, Samuel Leung, et al.

International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 5, 2025

Co-existent endometrial and ovarian carcinoma: molecular and pathological features define low risk entityAmy Jamieson, Jutta Huvila, Samuel Leung, et al.

Human Pathology|April 29, 2014

ARID1A/BAF250a as a prognostic marker for gastric carcinoma: a study of 2 cohortsKimberly C Wiegand, Keiyan Sy, Steve E Kalloger, et al.

Cancer Research|July 24, 2021

International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|July 31, 2018

Tubo-Ovarian Transitional Cell Carcinoma and High-grade Serous Carcinoma Show Subtly Different Immunohistochemistry ProfilesJamie Magrill, Anthony N Karnezis, Basile Tessier-Cloutier, et al.

NPJ Precision Oncology|July 19, 2024

Learning generalizable AI models for multi-center histopathology image classificationMaryam Asadi-Aghbolaghi, Amirali Darbandsari, Allen Zhang, et al.

The Journal of Pathology|August 29, 2012

The autophagy protein LC3A correlates with hypoxia and is a prognostic marker of patient survival in clear cell ovarian cancerJaeline E Spowart, Katelin N Townsend, Hassan Huwait, et al.

Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 27, 2016

Concurrent ARID1A and ARID1B inactivation in endometrial and ovarian dedifferentiated carcinomasMackenzie Coatham, Xiaodong Li, Anthony N Karnezis, et al.

Pageof 32